Unsure which funding opportunity is right for you? Use our investor matching tool to help you on to your next step
Find investorsTakes less than ~2 min to complete
We help entrepreneurs and venture capital fund managers turn promising ideas into market-defining and market-leading businesses. We are committed to spreading the Foundry Group ethos through our investment activity as well as in the other ways we engage with the entrepreneurial ecosystem.
I am an experienced asset manager, and I have held several executive positions throughout the banking and investment industry. The key word for my career has been client focus and a tireless development of the business potential, combined with a deep knowledge of the different elements in the asset management products, and a focus on the risk management and administrative set up. I belive in attracting skilled people by practicing an inclusive management style
Xecced Ventures is an impact investing venture capital firm that focuses on industry 4.0. It was spun out of think tank Xecced LLP in 2019. Xecced Ventures currently active fund is $100m 4thIRiA I Africa-focused fund, which invests in seed to early stages of start-up funding rounds. The $100m 4thIRiA I fund is Africa’s first artificial intelligence (AI) fund.
We are a Copenhagen based venture capital company, investing in outstanding ICT companies with proof of product, 1st. class management and scalable business models. We work actively to ignite and enhance growth within our portfolio companies - through business development, internationalization and acquisitions Over the last 10 years we have executed more than 40 investment cycles, transforming companies – and eventually exited our investments through trade sales or market listings.
Please go to https://www.herlevhospital.dk/ccit-denmark/Sider/default.aspx for more information. In short CCIT comprise clinical and experimental expertise in tumor immunology. The Centre has approx. 25 employees; scientists, clinicians, PhD students, as well as technicians. The Centre has extensive experience in initiating clinical trials in cancer, and more than 100 cancer patients have been vaccinated with dendritic cell based therapeutic vaccinations and new facilities for GCP production of cellular products for clinical use was recently opened, enabling trials using adoptive cell transfer of tumor specific T cells.